LadRx Corporation Announces Intent to Seek FDA Marketing Approval for Aldoxorubicin Despite Resource Limitations
I'm PortAI, I can summarize articles.
LadRx Corporation announced its intent to seek FDA marketing approval for aldoxorubicin on December 11, 2024. The company plans to use existing clinical and supplemental non-clinical data under section 505(b)(2). However, it has determined that it currently lacks the necessary resources to proceed with the approval process. No information on potential funding or grants has been disclosed.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments